- Home
- IPM vs PULM Comparison
IPM vs PULM Comparison
Compare IPM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- PULM
- Stock Information
- Founded
- IPM 2005
- PULM 2003
- Country
- IPM United States
- PULM United States
- Employees
- IPM N/A
- PULM N/A
- Industry
- IPM
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- IPM
- PULM Health Care
- Exchange
- IPM NYSE
- PULM Nasdaq
- Market Cap
- IPM 27.9M
- PULM 28.3M
- IPO Year
- IPM N/A
- PULM N/A
- Fundamental
- Price
- IPM $2.10
- PULM $8.90
- Analyst Decision
- IPM Strong Buy
- PULM
- Analyst Count
- IPM 1
- PULM 0
- Target Price
- IPM $6.00
- PULM N/A
- AVG Volume (30 Days)
- IPM 90.4K
- PULM 22.7K
- Earning Date
- IPM 05-14-2025
- PULM 05-15-2025
- Dividend Yield
- IPM N/A
- PULM N/A
- EPS Growth
- IPM N/A
- PULM N/A
- EPS
- IPM N/A
- PULM N/A
- Revenue
- IPM $6,344,746.00
- PULM $1,921,000.00
- Revenue This Year
- IPM $1,957.49
- PULM N/A
- Revenue Next Year
- IPM $17.96
- PULM $134.88
- P/E Ratio
- IPM N/A
- PULM N/A
- Revenue Growth
- IPM 14.16
- PULM N/A
- 52 Week Low
- IPM $1.52
- PULM $1.78
- 52 Week High
- IPM $5.50
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- PULM 65.51
- Support Level
- IPM N/A
- PULM $8.49
- Resistance Level
- IPM N/A
- PULM $9.16
- Average True Range (ATR)
- IPM 0.00
- PULM 0.67
- MACD
- IPM 0.00
- PULM 0.22
- Stochastic Oscillator
- IPM 0.00
- PULM 85.63
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powers multimedia social applications.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).